The role of galectin-3 in the tumorigenesis and progression of pituitary tumors

Diao,Bo; Liu,Ying; Xu,Guo‑Zheng; Zhang,Yi; Xie,Jun; Gong,Jie

doi:10.3892/ol.2018.7931

April-2018 Volume 15 Issue 4

Full Size Image

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

An International Open Access Journal Devoted to General Medicine.

April-2018 Volume 15 Issue 4

Full Size Image

Article Open Access

The role of galectin-3 in the tumorigenesis and progression of pituitary tumors

Authors:
- Bo Diao
- Ying Liu
- Guo‑Zheng Xu
- Yi Zhang
- Jun Xie
- Jie Gong
View Affiliations / Copyright

Affiliations: Department of Neurosurgery, Wuhan General Hospital of Guangzhou Command and Hubei Key Laboratory of Central Nervous System Tumor and Intervention, Wuhan, Hubei 430070, P.R. China, Department of Clinical Laboratory, Wuhan General Hospital of Guangzhou Command, Wuhan, Hubei 430070, P.R. China, Department of Clinical Experiment, Wuhan General Hospital of Guangzhou Command, Wuhan, Hubei 430070, P.R. China, Department of Science and Training, Wuhan General Hospital of Guangzhou Command, Wuhan, Hubei 430070, P.R. China

Copyright: © Diao et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
Pages: 4919-4925
|
Published online on: February 2, 2018

https://doi.org/10.3892/ol.2018.7931
Expand metrics +

Abstract

Galectin-3 (Gal-3), a β-galactoside-binding protein, has been implicated in cell proliferation, cell adhesion, and the progression and metastasis of various types of cancer. The present study investigated the involvement of Gal‑3 in the tumorigenesis and progression of pituitary tumors using three rat pituitary tumor cell lines. Following transfection with Gal-3 expression and interference vectors, the impact of Gal‑3 on proliferation, apoptosis and migration of pituitary tumor cells was been investigated. Meanwhile, BCL2 associated X, apoptosis regulator (Bax), caspase‑3 and matrix metalloproteinase 7 (MMP7) protein expression levels were analyzed by western blotting. The results of the present study revealed that Gal‑3 expression in GH3 and GH4C1 cells was higher than in RC‑4B/C cells. Furthermore, Gal‑3 was demonstrated to promote the proliferation and migration of GH3 and GH4C1 cells, and inhibit cell apoptosis. Caspase‑3 and MMP7 protein expression was also increased by Gal‑3, while Bax expression was decreased. These results suggested that Gal‑3 serves an important function in the tumorigenesis and development of pituitary tumors, and it may be a useful target for the treatment of pituitary tumors in the future.

View Figures

View References

1	Jiang X and Zhang X: The molecular pathogenesis of pituitary adenomas: An update. Endocrinol Metab (Seoul). 28:245–254. 2013. View Article : Google Scholar : PubMed/NCBI
2	Chatzellis E, Alexandraki KI, Androulakis II and Kaltsas G: Aggressive pituitary tumors. Neuroendocrinology. 101:87–104. 2015. View Article : Google Scholar : PubMed/NCBI
3	Gong J, Diao BO, Yao GJ, Liu Y and Xu GZ: Analysis of regulatory networks constructed based on gene coexpression in pituitary adenoma. J Genet. 92:489–497. 2013. View Article : Google Scholar : PubMed/NCBI
4	Huang CX, Hou YH and Liu YS: Expression of galectin-3 correlates with apoptosis in pituitary adenoma cells. Neurosci Bull. 24:34–38. 2008. View Article : Google Scholar : PubMed/NCBI
5	Arfaoui-Toumi A, Kria-Ben Mahmoud L, Ben Hmida M, Khalfallah MT, Regaya-Mzabi S and Bouraoui S: Implication of the galectin-3 in colorectal cancer development (about 325 tunisian patients). Bull Cancer. 97:E1–E8. 2010.PubMed/NCBI
6	Manivannan P, Siddaraju N, Jatiya L and Verma SK: Role of pro-angiogenic marker galectin-3 in follicular neoplasms of thyroid. Indian J Biochem Biophys. 49:392–394. 2012.PubMed/NCBI
7	Yamaki S, Fujii T, Yajima R, Hirakata T, Yamaguchi S, Fujisawa T, Tsutsumi S, Asao T, Yanagita Y, Iijima M and Kuwano H: Clinicopathological significance of decreased galectin-3 expression and the long-term prognosis in patients with breast cancer. Surg Today. 43:901–905. 2013. View Article : Google Scholar : PubMed/NCBI
8	Huang CX, Zhao JN, Zou WH, Li JJ, Wang PC, Liu CH and Wang YB: Reduction of galectin-3 expression reduces pituitary tumor cell progression. Genet Mol Res. 13:6892–6898. 2014. View Article : Google Scholar : PubMed/NCBI
9	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
10	Na YJ, Jeon YJ, Suh JH, Kang JS, Yang KH and Kim HM: Suppression of IL-8 gene expression by radicicol is mediated through the inhibition of ERK1/2 and p38 signaling and negative regulation of NF-kappaB and AP-1. Int Immunopharmacol. 1:1877–1887. 2001. View Article : Google Scholar : PubMed/NCBI
11	Liu FT and Rabinovich GA: Galectins as modulators of tumour progression. Nat Rev Cancer. 5:29–41. 2005. View Article : Google Scholar : PubMed/NCBI
12	Newlaczyl AU and Yu LG: Galectin-3-a jack-of-all-trades in cancer. Cancer Lett. 313:123–128. 2011. View Article : Google Scholar : PubMed/NCBI
13	Riss D, Jin L, Qian X, Bayliss J, Scheithauer BW, Young WF Jr, Vidal S, Kovacs K, Raz A and Lloyd RV: Differential expression of galectin-3 in pituitary tumors. Cancer Res. 63:2251–2255. 2003.PubMed/NCBI
14	Righi A, Jin L, Zhang S, Stilling G, Scheithauer BW, Kovacs K and Lloyd RV: Identification and consequences of galectin-3 expression in pituitary tumors. Mol Cell Endocrinol. 326:8–14. 2010. View Article : Google Scholar : PubMed/NCBI
15	Park SH, Min HS, Kim B, Myung J and Paek SH: Galectin-3: A useful biomarker for differential diagnosis of brain tumors. Neuropathology. 28:497–506. 2008. View Article : Google Scholar : PubMed/NCBI

Journals

International Journal of Molecular Medicine

International Journal of Oncology

Molecular Medicine Reports

Oncology Reports

Experimental and Therapeutic Medicine

Oncology Letters

Biomedical Reports

Molecular and Clinical Oncology

World Academy of Sciences Journal

International Journal of Functional Nutrition

International Journal of Epigenetics

Medicine International

The role of galectin-3 in the tumorigenesis and progression of pituitary tumors

This article is mentioned in:

Abstract

Figure 1

Figure 2

Figure 3

Figure 4

Figure 5

Related Articles